<DOC>
	<DOCNO>NCT02077335</DOCNO>
	<brief_summary>The purpose study determine clinical efficacy toxicity High-dose rate ( HDR ) brachytherapy monotherapy treatment low risk intermediate risk prostate cancer .</brief_summary>
	<brief_title>Study High-dose Rate ( HDR ) Monotherapy Low Intermediate Risk Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Biopsy proven Adenocarcinoma Prostate Clinical stage T1c , T2a T2b PSA le 20 ng/ml Gleason Score 6 7 Age less 18 year Clinical stage T2c , T3 ou T4 Clinical Stage N1 Clinical Stage M1 Prostate Specific Antigen ( PSA ) 20 ng/ml Gleason score 8 high IPSS score 19 high alphablockers Past radiation therapy pelvis History Collagen Vascular Disease History Inflammatory Bowel Disease Bilateral Hip Prosthesis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Brachytherapy</keyword>
	<keyword>Monotherapy</keyword>
	<keyword>HDR</keyword>
</DOC>